BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Post-LOEbuprenorphine hydrochloride and naloxone hydrochloride dihydrate
ANDASUBLINGUALTABLET
Approved
Jul 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (buprenorphine hydrochloride and naloxone hydrochloride dihydrate) by Hikma is naloxone. First approved in 2020.
Drug data last refreshed 1w ago
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Hikma
NJ - Berkeley Heights
Worked on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.